Unlock Insights into Stroke Research | Specialized Experimental Model Solutions
This brochure highlights the 4-VO and 2-VO models, enabling clients to study the molecular mechanisms of ischemic brain injury and evaluate new therapeutic approaches.
The 4-VO model induces transient forebrain ischemia resembling cardiac arrest, leading to delayed neuronal death, astrocyte hypertrophy, and microglial activation. The 2-VO model produces gradual cerebral hypoperfusion, ideal for studying selective neuronal injury and white matter pathology such as demyelination and gliosis.
Detailed procedures outline vessel ligation and occlusion steps, ischemia durations, and recovery phases. Validation indicators include EEG flattening and reduced LDH activity, confirming successful ischemia and reperfusion outcomes.
These models support research on the molecular mechanisms of cardiac arrest-induced brain injury, evaluation of neuroprotective therapies, and exploration of ischemia-related neuronal and glial responses.
Download the brochure to explore how our validated ischemia models can enhance the reliability and translational impact of your preclinical stroke studies.
tMCAO model is a widely used to mimic focal cerebral ischemia followed by reperfusion, enabling the study of disease mechanisms and potential therapies.
Ace Therapeutics provides customized stroke models and technology platforms to support preclinical stroke research.
pMCAO model is a widely used to simulate permanent focal cerebral ischemia, mimicking the occlusion seen in human ischemic stroke without reperfusion.
Photochemical thrombosis is a method for the induction of ischemic stroke in the cerebral cortex, which aids in stroke mechanism and therapy development.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.